Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares in the company, valued at approximately $5,862,252.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $69.02, for a total transaction of $552,160.00.

Vaxcyte Stock Performance

Vaxcyte stock opened at $60.88 on Wednesday. The company has a market capitalization of $6.62 billion, a PE ratio of -14.74 and a beta of 0.89. The company has a 50 day moving average price of $68.83 and a 200-day moving average price of $61.29. Vaxcyte, Inc. has a fifty-two week low of $41.57 and a fifty-two week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period last year, the firm posted ($0.73) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. Parallel Advisors LLC lifted its position in shares of Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Banque Cantonale Vaudoise lifted its holdings in Vaxcyte by 96.7% during the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after buying an additional 582 shares during the period. Avior Wealth Management LLC bought a new stake in Vaxcyte during the 3rd quarter valued at $178,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Vaxcyte in the 4th quarter valued at $208,000. Finally, Rathbones Group PLC purchased a new stake in shares of Vaxcyte during the 3rd quarter worth $221,000. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Bank of America boosted their target price on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $78.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.